A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
maintenance therapy
measurable residual disease
quality of life
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
revised:
14
09
2024
received:
02
08
2024
accepted:
20
09
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
LAMVYX was a multicenter, single-arm, phase 2 trial designed to validate the safety and efficacy of CPX-351 in patients aged 60-75 years with newly diagnosed, secondary acute myeloid leukemia and to generate evidence on key issues not addressed in the preceding regulatory pivotal trial. The primary end point of the study was the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate after induction. Eligible patients were recommended to undergo allogeneic hematopoietic stem cell transplantation after the first consolidation cycle. Alternatively, patients could undergo up to six maintenance cycles with CPX-351. Twenty-nine patients (49%; 95% exact confidence interval [CI], 37%-62%) patients achieved a CR/CRi after one or two cycles of induction, with a measurable residual disease negativity rate of 67% as assessed by centralized, multiparameter flow cytometry. Among patients who had serial next-generation sequencing analyses available, clearance of somatic mutations that were present at diagnosis was achieved in 7 (35%). The median follow-up among survivors was 16.8 months (range, 8.7-24.3 months). The median event-free survival was 3.0 months (95% CI, 1.4-7.3 months), and the median overall survival was 7.4 months (95% CI, 3.7-12.7 months). In landmark analyses at day +100 from diagnosis, the 1-year overall and event-free survival rate among patients who underwent allogeneic hematopoietic stem cell transplantation was 70% (95% CI, 47%-100%) and 70% (95% CI, 47%-100%), respectively. The corresponding values were 89% (95% CI, 71%-100%) and 44% (95% CI, 21%-92%), respectively, for patients who entered the maintenance phase. No significant longitudinal changes were observed in severity index or quality-of-life visual analog scale scores. The current data provide novel insights that might inform the clinical positioning and optimal use of CPX-351, complementing previous results (ClinicalTrials.gov identifier NCT04230239).
Sections du résumé
BACKGROUND
BACKGROUND
LAMVYX was a multicenter, single-arm, phase 2 trial designed to validate the safety and efficacy of CPX-351 in patients aged 60-75 years with newly diagnosed, secondary acute myeloid leukemia and to generate evidence on key issues not addressed in the preceding regulatory pivotal trial.
METHODS
METHODS
The primary end point of the study was the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate after induction. Eligible patients were recommended to undergo allogeneic hematopoietic stem cell transplantation after the first consolidation cycle. Alternatively, patients could undergo up to six maintenance cycles with CPX-351.
RESULTS
RESULTS
Twenty-nine patients (49%; 95% exact confidence interval [CI], 37%-62%) patients achieved a CR/CRi after one or two cycles of induction, with a measurable residual disease negativity rate of 67% as assessed by centralized, multiparameter flow cytometry. Among patients who had serial next-generation sequencing analyses available, clearance of somatic mutations that were present at diagnosis was achieved in 7 (35%). The median follow-up among survivors was 16.8 months (range, 8.7-24.3 months). The median event-free survival was 3.0 months (95% CI, 1.4-7.3 months), and the median overall survival was 7.4 months (95% CI, 3.7-12.7 months). In landmark analyses at day +100 from diagnosis, the 1-year overall and event-free survival rate among patients who underwent allogeneic hematopoietic stem cell transplantation was 70% (95% CI, 47%-100%) and 70% (95% CI, 47%-100%), respectively. The corresponding values were 89% (95% CI, 71%-100%) and 44% (95% CI, 21%-92%), respectively, for patients who entered the maintenance phase. No significant longitudinal changes were observed in severity index or quality-of-life visual analog scale scores.
CONCLUSIONS
CONCLUSIONS
The current data provide novel insights that might inform the clinical positioning and optimal use of CPX-351, complementing previous results (ClinicalTrials.gov identifier NCT04230239).
Banques de données
ClinicalTrials.gov
['NCT04230239']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Jazz Pharmaceuticals
Informations de copyright
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Récher C, Röllig C, Bérard E, et al. Long‐term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022;36(4):913‐922. doi:10.1038/s41375‐021‐01425‐9
Martínez‐Cuadrón D, Serrano J, Gil C, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. 2021;35(6):1571‐1585. doi:10.1038/s41375‐020‐01058‐4
Pratz KW, Jonas BA, Pullarkat V, et al. Long‐term follow‐up of VIALE‐A: venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615‐624, doi:10.1002/ajh.27246
Bazinet A, Kantarjian H, Arani N, et al. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023;98(9):1383‐1393. doi:10.1002/ajh.26997
Pagano L, Pulsoni A, Tosti ME, et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol. 2001;112(1):109‐117. doi:10.1046/j.1365‐2141.2001.02527.x
Xu XQ, Wang JM, Gao L, et al. Characteristics of acute myeloid leukemia with myelodysplasia‐related changes: a retrospective analysis in a cohort of Chinese patients. Am J Hematol. 2014;89(9):874‐881. doi:10.1002/ajh.23772
Østgård LSG, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy‐related acute myeloid leukemia: a national population‐based cohort study. J Clin Oncol. 2015;33(31):3641‐3649. doi:10.1200/jco.2014.60.0890
Hulegårdh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208‐214. doi:10.1002/ajh.23908
Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367‐1376. doi:10.1182/blood‐2014‐11‐610543
Martínez‐Cuadrón D, Megías‐Vericat JE, Serrano J, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278‐1295. doi:10.1182/bloodadvances.2021005335
Lazarevic V, Hörstedt AS, Johansson B, et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population‐based experience. Blood Cancer J. 2014;4(2):e188. doi:10.1038/bcj.2014.10
Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546‐2557. doi:10.1038/s41375‐018‐0257‐z
Lancet JE, Uy GL, Cortes JE, et al. Cpx‐351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684‐2692. doi:10.1200/jco.2017.77.6112
Lancet JE, Uy GL, Newell LF, et al. CPX‐351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high‐risk or secondary acute myeloid leukaemia: 5‐year results of a randomised, open‐label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481‐e491. doi:10.1016/S2352‐3026(21)00134‐4
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912‐2919. doi:10.1182/blood‐2005‐05‐2004
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391‐2405. doi:10.1182/blood‐2016‐03‐643544
Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642‐4649. doi:10.1200/jco.2003.04.036
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. doi:10.1182/blood.2022016867
Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354‐365. doi:10.1182/blood‐2009‐11‐254441
Kalina T, Flores‐Montero J, Van Der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986‐2010. doi:10.1038/leu.2012.122
Megías‐Vericat JE, Martínez‐Cuadrón D, López JM, et al. Differences in ex‐vivo chemosensitivity to anthracyclines in first line acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2019;11(1):e2019016. doi:10.4084/MJHID.2019.016
Martínez‐Cuadrón D, Gil C, Serrano J, et al. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res. 2019;76:1‐10. doi:10.1016/j.leukres.2018.11.006
Bennett TA, Montesinos P, Moscardo F, et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014;14(4):305‐318. doi:10.1016/j.clml.2013.11.006
Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753‐2767, doi:10.1182/blood.2021013626
Bernal T, Moreno AF, de LaIglesia A, et al. Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: a comparison with a matched cohort from the Spanish PETHEMA registry. Cancer Med. 2023;12(14):14892‐14901. doi:10.1002/cam4.6120
Guolo F, Fianchi L, Minetto P, et al. CPX‐351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10(10):96. doi:10.1038/s41408‐020‐00361‐8
Chiche E, Rahme R, Bertoli S, et al. Real‐life experience with CPX‐351 and impact on the outcome of high‐risk AML patients: a multicentric French cohort. Blood Adv. 2021;5(1):176‐184. doi:10.1182/bloodadvances.2020003159
Rautenberg C, Stölzel F, Röllig C, et al. Real‐world experience of CPX‐351 as first‐line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021;11(10):164. doi:10.1038/s41408‐021‐00558‐5
Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526‐2537. doi:10.1056/nejmoa2004444
Cortes JE, Lin TL, Uy GL, Ryan RJ, Faderl S, Lancet JE. Quality‐adjusted Time Without Symptoms of disease or Toxicity (Q‐TWiST) analysis of CPX‐351 versus 7 + 3 in older adults with newly diagnosed high‐risk/secondary AML. J Hematol Oncol. 2021;14(1):110. doi:10.1186/s13045‐021‐01119‐w
Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417‐4423. doi:10.1200/jco.2011.35.7525
Sasaki K, Kadia T, Begna K, et al. Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97(1):68‐78. doi:10.1002/ajh.26395
Hochman MJ, Othus M, Hasserjian RP, et al. Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification. Leukemia. 2023;37(9):1915‐1918. doi:10.1038/s41375‐023‐01985‐y
Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX‐351 vs 7 + 3 in older adults with newly diagnosed high‐risk and/or secondary AML. Blood Adv. 2022;6(17):4989‐4993. doi:10.1182/bloodadvances.2021006468
Tazi Y, Arango‐Ossa JE, Zhou Y, et al. Unified classification and risk‐stratification in acute myeloid leukemia. Nat Commun. 2022;13(1):4622. doi:10.1038/s41467‐022‐32103‐8
Maffini E, Labopin M, Beelen DW, et al. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2022;57(10):1556‐1563. doi:10.1038/s41409‐022‐01748‐w
Rodríguez‐Arbolí E, Orvain C, Othus M, Walter RB. Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2022;57(11):1732‐1734. doi:10.1038/s41409‐022‐01794‐4
Jongen‐Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189‐1199. doi:10.1056/nejmoa1716863
Matthews AH, Perl AE, Luger SM, et al. Real‐world effectiveness of CPX‐351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997‐4005. doi:10.1182/bloodadvances.2022007265